New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
10:24 EDTFST, TXT, USB, STI, JNJ, ESE, HRL, PLL, URBN, TXRH, ZQK, ILMN, C, ARUN, TOWR, UA, TGT, MAT, FRC, CAHOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Cardinal Health (CAH) upgraded to Buy from Neutral at Mizuho... Citigroup (C) upgraded to Conviction Buy from Buy at Goldman... ESCO Technologies (ESE) upgraded to Outperform from Neutral at RW Baird... First Republic Bank (FRC) upgraded to Buy from Hold at Deutsche Bank... Illumina (ILMN) upgraded to Overweight from Neutral at Piper Jaffray... Johnson & Johnson (JNJ) upgraded to Buy from Hold at Deutsche Bank... Mattel (MAT) upgraded to Buy from Hold at Needham... Quiksilver (ZQK) upgraded to Buy from Neutral at Goldman... SunTrust (STI) upgraded to Buy from Neutral at Goldman... Target (TGT) upgraded to Buy from Neutral at Janney Capital... Texas Roadhouse (TXRH) upgraded to Buy from Hold at Deutsche Bank... U.S. Bancorp (USB) upgraded to Buy from Hold at Deutsche Bank... Under Armour (UA) upgraded to Outperform from Neutral at Credit Suisse... Urban Outfitters (URBN) upgraded to Outperform from Neutral at Credit Suisse... Textron (TXT) upgraded to Outperform from Neutral at Credit Suisse... Tower International (TOWR) upgraded to Neutral from Underweight at JPMorgan... Pall Corp. (PLL) upgraded to Neutral from Underperform at Macquarie... Forest Oil (FST) upgraded to Market Perform from Underperform at Raymond James... Aruba Networks (ARUN) upgraded to Buy from Hold at Stifel Nicolaus... Hormel Foods (HRL) upgraded to Outperform from Underperform at CLSA.
News For CAH;C;ESE;FRC;ILMN;JNJ;MAT;ZQK;STI;TGT;TXRH;USB;UA;URBN;TXT;TOWR;PLL;FST;ARUN;HRL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 9, 2014
07:37 EDTTOWRUBS to hold a conference
Subscribe for More Information
07:05 EDTPLLPall Corp. announces resignation of CFO Akhil Johri
Subscribe for More Information
07:03 EDTPLLUnited Technologies appoints Akhil Johri as Senior VP and CFO
Subscribe for More Information
06:10 EDTFSTForest Oil receives continued listing standards notice from NYSE
Subscribe for More Information
05:59 EDTCCitigroup appointed successor depositary bank for Deutsche Post ADR program
Citi (C), acting through Citibank N.A., has been appointed by Deutsche Post AG (DPSGY) as successor depositary bank for its Level 1 American Depositary Receipt, or ADR, program. Deutsche Post DHL’s ADR program trades in the U.S. over the counter market, with each ordinary share equivalent to 1 ADR.
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
16:55 EDTCLone Star joins Springleaf as bidder for Citigroup OneMain unit, Bloomberg says
Subscribe for More Information
16:00 EDTCOptions Update; December 8, 2014
Subscribe for More Information
15:40 EDTCLone Star joins Springleaf as bidder for Citigroup OneMain unit, Bloomberg says
11:48 EDTSTISunTrust downgraded to Hold from Buy at Standpoint Research
11:30 EDTCAHLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
10:00 EDTUSBOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:37 EDTTXTTextron Aerosonde SUAS receives FAA Certificate of Authorization for NAS
Subscribe for More Information
08:02 EDTARUNAruba says NHS replaces Cisco network with Aruba wireless infrastructure
Subscribe for More Information
06:35 EDTC, USBValue of Wall Street's M&A bankers has risen, NY Times says
The value of Wall Street's bankers who advise large companies seems to be increasing, while traders are becoming less valuable, according to The New York Times. Bankers who work on M&A deals are expecting their bonuses to increase, while traders anticipate that their compensation will drop, the newspaper added. Furthermore, banks seem to be going the extra mile to hire top notch bankers, the newspaper stated. Publicly traded large banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
06:21 EDTCDeadline for Petsmart bidders extended as lenders put on leash, NY Post reports
Subscribe for More Information
05:59 EDTUSBU.S. Bancorp downgraded to Underperform from Market Perform at Keefe Bruyette
Subscribe for More Information
December 7, 2014
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use